There are 1105 resources available
644P - Tifcemalimab combined with toripalimab and docetaxel as 2nd line treatment for immunotherapy-treated squamous cell non-small cell lung cancer (Sq-NSCLC) patients: A phase Ib/II study
Presenter: Dongqing Lv
Session: Poster Display session
Resources:
Abstract
645P - The Impact of driver gene alteration type on the efficacy of immune checkpoint inhibitors
Presenter: Hajime Tsuruoka
Session: Poster Display session
Resources:
Abstract
646P - Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for epidermal growth factor receptor inhibitor (EGFRi)-resistant, EGFR-mutant, advanced non-small cell lung cancer (NSCLC): Updated results from Cohort 5 in the DUBHE-L-201 study
Presenter: Wen Feng Fang
Session: Poster Display session
Resources:
Abstract
647P - A phase Ib/II study of second-line cadonilimab, anlotinib and docetaxel in patients with checkpoint inhibitor (CPI)-experienced advanced non-small cell lung cancer
Presenter: Yanwei Zhang
Session: Poster Display session
Resources:
Abstract
648P - The efficacy of ICIs plus platinum-based chemotherapy for patients with advanced NSCLC and ECOG PS 2 (WJOG18424L): A propensity score-matched study
Presenter: Shunichi Kataoka
Session: Poster Display session
Resources:
Abstract
649P - An oral, chemo-free regimen (osimertinib plus anlotinib) as first-line treatment for EGFR-mutated advanced NSCLC (AUTOMAN): Safety and survival outcome
Presenter: Baohui Han
Session: Poster Display session
Resources:
Abstract
650P - Impact of different lymph node status on prognosis in patients with non-small cell lung cancer after neoadjuvant chemoimmunotherapy: A multicenter retrospective cohort study
Presenter: Ran Ma
Session: Poster Display session
Resources:
Abstract
651P - Efficacy and safety outcomes of Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study): Long-term follow-up analysis
Presenter: Yongfeng Yu
Session: Poster Display session
Resources:
Abstract
652P - 3-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer
Presenter: Claire Verschraegen
Session: Poster Display session
Resources:
Abstract
653P - Baseline and 3 weeks on-treatment plasma EGFR mutation (EGFRm) dynamics in patients with EGFR mutant advanced NSCLC treated with first-line osimertinib: A prospective, multi-center, real-world analysis
Presenter: Jie Wang
Session: Poster Display session
Resources:
Abstract